🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gerald S. Falchook

Sarah Cannon Research Institute

ORCID: 0000-0001-9165-2191

Also affiliated with Sarah Cannon, HealthONE

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Papers

Driven by 10 papers — median percentile 0. Top paper: “Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours”.

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

British Journal of Cancer(2020)10.1038/s41416-020-0802-1
N/A
3.4DataRank · unranked
924 citations

Yoon‐Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi, Ho Yeong Lim +18 more

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Nature Medicine(2024)10.1038/s41591-023-02717-6
N/A
2.0DataRank · unranked
94 citations

Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim +14 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215
N/A
1.3DataRank · unranked
41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Cancer Research(2025)10.1158/0008-5472.can-25-0998
N/A
0.104DataRank · unranked
1 citations

Soumyadip Sahu, Minjie Zhang, Ayushi S. Patel, Ke Geng, Reshmee Bhattacharya +47 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects

Molecular Therapy(2025)10.1016/j.ymthe.2025.08.027
N/A
0DataRank · unranked
2 citations

Jordi Rodon, Shree Venkat, Arthur Donahue, Amber Thomassen, William P. Accomando +10 more

134TiP: Evaluation of an additional cohort of patients with non-small cell lung cancer (NSCLC) in the phase I/II duravelo-1 study of zelenectide pevedotin (BT8009), a bicycle toxin conjugate

Journal of Thoracic Oncology(2025)10.1016/s1556-0864(25)00329-6
N/A
0DataRank · unranked
0 citations

Loïc Verlingue, A. Italiano, L. Carter, Gerald S. Falchook, Valentina Boni +13 more

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

ESMO Open(2021)10.1016/j.esmoop.2021.100079
N/A
0DataRank · unranked
13 citations

Ruth Sacks, Ishwaria M. Subbiah, Neele Drobnitzky, Sarina A. Piha‐Paul, David S. Hong +15 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256
N/A
0DataRank · unranked
98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Fosciclopirox clinical proof of concept in patients with nonmuscle invasive and muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16557
N/A
0DataRank · unranked
2 citations

Elizabeth R. Kessler, Janet Baack Kukreja, Gerald S. Falchook, Manojkumar Bupathi, Rahul Atul Parikh +15 more